Your browser doesn't support javascript.
loading
Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V2) Therapy.
Roche, Kyle C; DeRosa, Peter A; Liu, Min-Ling; Nava, Victor E; Aggarwal, Anita.
Afiliação
  • Roche KC; Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
  • DeRosa PA; Department of Pathology, The University of Maryland Medical Center, Baltimore, MD 21201, USA.
  • Liu ML; Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
  • Nava VE; Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA.
  • Aggarwal A; Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Curr Oncol ; 29(6): 4117-4124, 2022 06 06.
Article em En | MEDLINE | ID: mdl-35735437
ABSTRACT
Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V2), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esplênicas / Leucemia Linfocítica Crônica de Células B / Linfoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Curr Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esplênicas / Leucemia Linfocítica Crônica de Células B / Linfoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Curr Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos